DelveInsight’s “Scabies Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Scabies, historical and forecasted epidemiology as well as the Scabies market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Scabies market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Scabies market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Scabies Market Insights
Scabies Overview
Scabies is a contagious ectoparasitic condition caused by the infestation of the skin by the human itch mite (Sarcoptes scabiei var. hominis). The microscopic mite burrows into the skin and lays eggs, eventually triggering a host immune response that leads to intense itching and rash. Scabies infestation may be complicated by bacterial infection, leading to the development of skin sores that, in turn, may lead to the development of more serious consequences such as septicaemia, heart disease and chronic kidney disease.
Some of the key facts of the Scabies Market Report:
- The Scabies market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- According to Goldstein et al., the worldwide prevalence is estimated to be 200 million people, with wide variation in prevalence among individual geographic regions
- According to Romani et al., scabies was more common in females (39.2% versus 33.7%). The distribution of scabies lesions was similar in both genders, with the exception of the perineum and buttocks areas, where scabies was more observed in females
- Key Scabies Companies: Medicines development for global health, Infectopharm Arzneimittel GmbH, Mylan Laboratories, and others
- Key Scabies Therapies: Moxidectin, InfectoScab 5% cream, Permethrin Foam 4%, and others
- The Scabies epidemiology based on gender analyzed that females are more prevalent for scabies as compared to males. It has been found that 39.2% females and 33.7% male are affected by scabies
Get a Free sample for the Scabies Market Report –
https://www.delveinsight.com/sample-request/scabies-market
Key benefits of the Scabies Market report:
- Scabies market report covers a descriptive overview and comprehensive insight of the Scabies Epidemiology and Scabies market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Scabies market report provides insights on the current and emerging therapies.
- Scabies market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Scabies market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Scabies market.
Download the report to understand which factors are driving Scabies epidemiology trends @ Scabies Epidemiological Insights
Scabies Market
The dynamics of the Scabies market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
“Factors like recent approval of Natroba topical suspension, as a targeted topical therapy for the treatment of scabies, steps taken by regulators to improve clinical studies (For instance: FDA defined objective criteria for ‘complete cure’ and inclusion of framework for scabies control by WHO), are likely to drive market growth during the forecast period (2019-2032).”
Scabies Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Scabies Epidemiology Segmentation:
The Scabies market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Scabies
- Prevalent Cases of Scabies by severity
- Gender-specific Prevalence of Scabies
- Diagnosed Cases of Episodic and Chronic Scabies
Scabies Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Scabies market or expected to get launched during the study period. The analysis covers Scabies market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Scabies Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major Scabies market share @ Scabies market forecast
Scabies Therapies and Key Companies
- Moxidectin: Medicines development for global health
- InfectoScab 5% cream: Infectopharm Arzneimittel GmbH
- Permethrin Foam 4%: Mylan Laboratories
Scope of the Scabies Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Scabies Companies: Medicines development for global health, Infectopharm Arzneimittel GmbH, Mylan Laboratories, and others
- Key Scabies Therapies: Moxidectin, InfectoScab 5% cream, Permethrin Foam 4%, and others
- Scabies Therapeutic Assessment: Scabies current marketed and Scabies emerging therapies
- Scabies Market Dynamics: Scabies market drivers and Scabies market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Scabies Unmet Needs, KOL’s views, Analyst’s views, Scabies Market Access and Reimbursement
Table of Contents
1. Scabies Market Report Introduction
2. Executive Summary for Scabies
3. SWOT analysis of Scabies
4. Scabies Patient Share (%) Overview at a Glance
5. Scabies Market Overview at a Glance
6. Scabies Disease Background and Overview
7. Scabies Epidemiology and Patient Population
8. Country-Specific Patient Population of Scabies
9. Scabies Current Treatment and Medical Practices
10. Scabies Unmet Needs
11. Scabies Emerging Therapies
12. Scabies Market Outlook
13. Country-Wise Scabies Market Analysis (2019–2032)
14. Scabies Market Access and Reimbursement of Therapies
15. Scabies Market Drivers
16. Scabies Market Barriers
17. Scabies Appendix
18. Scabies Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Scabies treatment, visit @ Scabies Medications
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting